Webinars

Attendee Quick Reference Guide

Past Webinars

Download Archived Webinars
(Requires Member Login. After Login - Click on "AMP Web Library" in the Left Navigation Column.)

 

 

 

 

 

 

 

Association for Molecular Pathology

Future Webinars

2014 Webinars

For AMP Webinars that offer Continuing Education Credit:


AMP is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program and by the Florida Board of Clinical Laboratory Personnel.


Individual attendees requesting P.A.C.E. credit should use the form provided below. If you are viewing the webinar in a group setting, please use the P.A.C.E. Group Attendance Roster, below. Each group participant is required to print and sign his or her name and email address to verify attendance. Once the webinar has concluded, the designated "Site Coordinator" must email this group attendance form to Kathleen Carmody, P.A.C.E. Coordinator, in order for each participant to receive P.A.C.E. credit.

 

Please contact Kathleen Carmody via email with any questions.


NGS 101 Presentation #3: An Integrated Approach to Assay Selection and Validation

October 21, 2014 at 2:00pm Eastern

 

PACE Group Attendance Roster

 

PACE Individual Evaluation Form

 

 

Certificate of Attendance

 

 

Handout

 

 

Presenter: Monica J Basehore, PhD, FACMG, Greenwood Genetics Center, Greenwood, SC

 

Host: Matthew Hiemenz, MD, University of Pennsylvania Health System, Philadelphia, PA

 

Description:

This webinar will provide an overview of factors important in clinical NGS test development and validation guidelines for clinical NGS tests. The professional standards and guidelines for quality and compliance that have been developed to date will be discussed and aspects such as instrument validation, assay/test validation, quality management, proficiency testing, and the use of reference materials during routine testing will be emphasized.

Learning Objectives:
1. Recognize the factors important in clinical NGS test development.
2. Review guidelines for optimizing and validating clinical NGS tests and platforms.
3. Prepare to implement a quality management program to ensure accurate NGS test results.

Level of Instruction: Basic

AMP is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program and by the Florida Board of Clinical Laboratory Personnel.

Register Now


 

NGS 101 Presentation #4: Nomenclature in the Context of Next Generation Sequencing

October 29, 2014 at 1:00pm Eastern

 

PACE Group Attendance Roster

 

PACE Individual Evaluation Form

 

 

Certificate of Attendance

 

 

Handout

 

Presenter: Robert Daber, PhD, Bio-Reference Laboratories, Inc., Elmwood Park, NJ

 

Host: Jordan Laser, MD, North Shore - Long Island Jewish Health System, Lake Success, NY

 

Details Coming Soon!

 

 

Register Now

 

 

 

 


 

 

 

NGS 101 Presentation #5: The Role of the Pathologist in Reporting & Communicating Accurate and Succinct Results in the Genomic Era

November 7, 2014 at 2:30pm Eastern

 

 

PACE Group Attendance Roster

 

PACE Individual Evaluation Form

 

 

Certificate of Attendance

 

 

Handout

 

 

 

 

 

 

 

 


Presenter: Colin C Pritchard, MD, PhD, University of Washington, Seattle, WA

 

Host: Benjamin Pinsky, MD, PhD, Stanford University School of Medicine, Palo Alto, CA

 

Description:
Next-generation DNA sequencing technology is transforming clinical genetics, including for diagnosis of hereditary genetic conditions, and in tumor-based testing for precision cancer therapy. This new testing approach presents considerable challenges for pathology reporting. This presentation will review considerations related to pathologist reporting of next-generation sequencing results with a focus on germline cancer risk panels, tumor mutation hotspot panels, and comprehensive tumor sequencing panels.

Learning Objectives:
1.  Describe methods for predicting if a poorly-characterized genetic variant is benign or pathogenic.
2.  Explain how the quantity of DNA sequenced impacts the detection of incidental findings, and how this influences clinical reporting considerations
3.  List two ways that clinical reporting considerations are different between hereditary (germline) sequencing panels and tumor sequencing panels

Level of Instruction: Intermediate

AMP is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program and by the Florida Board of Clinical Laboratory Personnel.

 

Register Now